In contrast to most other malignancies, hepatocellular carcinoma (HCC), which accounts for
approximately 90% of primary liver cancers, arises almost exclusively in the setting of …

Abstract Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of
intensive research because of its crucial role in the pathogenesis of different diseases …

Obesity-induced chronic liver inflammation is a hallmark of nonalcoholic steatohepatitis
(NASH)—an aggressive form of nonalcoholic fatty liver disease. However, it remains unclear …

Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor
for end-stage liver diseases with no available therapies. Dysregulated immune responses …

A subset of patients with non-alcoholic fatty liver disease develop an inflammatory condition,
termed non-alcoholic steatohepatitis (NASH). NASH is characterised by hepatocellular …

The number of patients with nonalcoholic fatty liver diseases (NAFLD) including
nonalcoholic steatohepatitis (NASH), has been increasing. NASH causes cirrhosis and …

Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis and inflammation
and, in some patients, progressive fibrosis leading to cirrhosis. An understanding of the …

Natural killer (NK) cells are enriched in lymphocytes within the liver and have unique
phenotypic features and functional properties, including tumor necrosis factor–related …

Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic
tissues. In the liver, nonalcoholic fatty liver disease (NAFLD) is associated with hepatic …